Combination of 90Y- and 177Lu-labeled somatostatin analogs is superior for radionuclide therapy compared to 90Y- or 177Lu-labeled analogs only.

被引：0
|
作者：
De Jong, M [1 ]
Bernard, HF [1 ]
Breeman, WA [1 ]
Van Gameren, A [1 ]
Krenning, EP [1 ]
机构：
[1] Erasmus MC, Rotterdam, Netherlands
来源：
JOURNAL OF NUCLEAR MEDICINE | 2002年 / 43卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
446
引用
收藏
页码：123P / 124P
页数：2
相关论文
共 50 条
  • [31] 177Lu-Labeled Anticlaudin 6 Monoclonal Antibody for Targeted Therapy in Esophageal Cancer
    Du, Huan
    Hao, Xiaofei
    Lin, Binwei
    Tang, Mingming
    Wang, Decai
    Yang, Xia
    Wang, Jing
    Qin, Liling
    Yang, Yuchuan
    Du, Xiaobo
    JOURNAL OF NUCLEAR MEDICINE, 2025, 66 (03) : 377 - 384
  • [32] Prediction of myelotoxicity based on bone marrow radiation-absorbed dose:: Radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen
    Vallabhajosula, S
    Goldsmith, SJ
    Hamacher, KA
    Kostakoglu, L
    Konishi, S
    Milowski, MI
    Nanus, DM
    Bander, NH
    JOURNAL OF NUCLEAR MEDICINE, 2005, 46 (05) : 850 - 858
  • [33] Prospects of medium specific activity 177Lu in targeted therapy of prostate cancer using 177Lu-labeled PSMA inhibitor
    Chakraborty, Sudipta
    Chakravarty, Rubel
    Shetty, Priyalata
    Vimalnath, K. V.
    Sen, Ishita B.
    Dash, Ashutosh
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2016, 59 (09): : 364 - 371
  • [34] Combination therapy of 177 Lu and 90 Y Dotatate for treatment of neuroendocrine cancer
    Ashton, Ceri E.
    Jeans, Stephen P.
    Valle, Juan W.
    NUCLEAR MEDICINE COMMUNICATIONS, 2014, 35 (06) : 585 - 587
  • [35] Practical dosimetry of peptide receptor radionuclide therapy with 90Y-labeled somatostatin analogs
    Pauwels, S
    Barone, R
    Walrand, S
    Borson-Chazot, F
    Valkema, R
    Kvols, LK
    Krenning, EP
    Jamar, F
    JOURNAL OF NUCLEAR MEDICINE, 2005, 46 : 92S - 98S
  • [36] Comparison of the Therapeutic Response to Treatment with a 177Lu-Labeled Somatostatin Receptor Agonist and Antagonist in Preclinical Models
    Dalm, Simone U.
    Nonnekens, Julie
    Doeswijk, Gabriela N.
    de Blois, Erik
    van Gent, Dik C.
    Konijnenberg, Mark W.
    de Jong, Marion
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57 (02) : 260 - 265
  • [37] Comparative evaluation of radionuclide therapy using 90Y and 177Lu
    Hanaoka, Hirofumi
    Hashimoto, Kazuyuki
    Watanabe, Satoshi
    Matsumoto, Shojiro
    Sakashita, Tetsuya
    Watanabe, Shigeki
    Ishioka, Noriko S.
    Endo, Keigo
    ANNALS OF NUCLEAR MEDICINE, 2023, 37 (01) : 52 - 59
  • [38] Comparative evaluation of radionuclide therapy using 90Y and 177Lu
    Hirofumi Hanaoka
    Kazuyuki Hashimoto
    Satoshi Watanabe
    Shojiro Matsumoto
    Tetsuya Sakashita
    Shigeki Watanabe
    Noriko S. Ishioka
    Keigo Endo
    Annals of Nuclear Medicine, 2023, 37 : 52 - 59
  • [39] Streamlined Schemes for Dosimetry of 177Lu-Labeled PSMA Targeting Radioligands in Therapy of Prostate Cancer
    Kurth, Jens
    Heuschkel, Martin
    Tonn, Alexander
    Schildt, Anna
    Hakenberg, Oliver W.
    Krause, Bernd J.
    Schwarzenboeck, Sarah M.
    CANCERS, 2021, 13 (15)
  • [40] 177Lu-Labeled Heterodimeric Agent with High Stability Targeting Neovascularization for Tumor Radioligand Therapy
    Yang, Biao
    Shan, Changyu
    Lv, Xiaoying
    Song, Xiangming
    Zeng, Dexing
    An, Rui
    Lan, Xiaoli
    Gai, Yongkang
    JOURNAL OF MEDICINAL CHEMISTRY, 2025, 68 (03) : 3146 - 3156
12345